Nymox Director Robinson adds in the market again

Nymox Pharmaceutical Corporation {NASDAQ: NYMX} Director James Robinson acquired 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th.

The total consideration was $33,300.

Nymox Pharmaceutical Corporation {NASDAQ: NYMX} Director James Robinson acquired 10,000 shares of the company’s stock in a transaction that completed on Wednesday, July 20th.

The stock was acquired at an average price of $3.33 per share, with a total value of $33,300.00. Following the acquisition, Robinson now owns 2,870,050 shares in the company, valued at $9,557,266.50.

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company.

The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localised prostate cancer.

The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.